Chondroitin sulphate in the normal and rheumatoid synovial fluid

149

108

Objective. To investigate the correlation between joint disease and the composition of chondroitin sulfate in the joint fluid, unsaturated disaccharide isomers of chondroitin 4-sulfate (.1di-4S) and chondroitin 6-sulfate (.1di·6S) were measured in joint fluids obtained from patients with osteoarthritis (OA), rheumatoid arthritis (RA), or traumatic arthritis (TA).Methods. These pathologic joint fluids were digested with chondroitinase ABC, and the .1di·4S and .1di·6S produced were determined by high performance liquid chromatography combined with fluorometry.Results. Total content of .1di-4S plus .1di·6S was 71.8 ± 30.0 nmoles/ml (mean ± SD) in OA, 55.4 ± 29.3 nmoles/ml in RA, and 211 ± 149 nmoles/ml in TA joint fluids. The ratio of .1di·6S to .1di·4S was 3.81 ± 0.992 in OA, 1.13 ± 0.527 in RA, and 5.75 ± 2.46 in TA joint fluids. Differences between groups were statistically significant.Conclusion. These results strongly suggest that the levels of chondroitin sulfate isomers and the .1di-6S: .1di·4S ratio in joint fluid reflect the proteoglycan metabolism of joint tissues, particularly of articular cartilage; hence, they could be used to diagnose joint diseases

mentioning

confidence: 99%

Quantitation of chondroitin 4—sulfate and chondroitin 6—sulfate in pathologic joint fluid

Shinmei

Miyauchi

Machida

et al. 1992

149

108

“…Thus, we are able to detect and characterize, by immlunologic methods, cartilage proteoglycans and their fragments in synovial fluid. Earlier biochemical work revealed the presence of chondroitin sulfate in synovial fluid (19)(20)(21) and showed that there were increases in the CS content relative to that of hyaluronic acid (2Q,21). Others have described cartilage proteoglycan-like fragments in normal ox synovial fluid of molecular weight 250,000 (22).…”

mentioning

confidence: 99%

The immunologic detection and characterization of cartilage proteoglycan degradation products in synovial fluids of patients with arthritis

Witter

Webber

et al. 1987

102

Antibodies were used in radioimmunoassays with gel chromatography to detect the hyaluronic acidbinding region, core protein, and keratan sulfate of human cartilage protoeglycan in the synovial fluids of patients with rheumatoid arthritis, juvenile rheumatoid arthritis, and osteoarthritis. All fluids contained proteoglycan that was mainly included on Sepharose CL4B; this result indicates cleavage of proteoglycan (which is normally excluded). The hyaluronic acidbinding region was the smallest and most commonly detected fragment. It was relatively free of keratan sulfate and core protein, and it could sometimes bind to hyaluronic acid. Other larger fragments containing core protein and/or keratan sulfate were detected in every fluid.

“…In previous studies of proteoglycan metabolism in arthritis, investigators quantified proteoglycans as glycosaminoglycans that were released to blood (9, urine (6,7), and synovial fluid (8,9). Interpretation of these results has been hampered by difficulties in determining the source of the molecules that contain the glycosaminoglycans, since the character of these is not tissue-specific.…”

mentioning

confidence: 99%

Cartilage proteoglycans in synovial fluid and serum in patients with inflammatory joint disease. relation to systemic treatment

Saxne

Heinegård

Wollheim

1987

Proteoglycan concentrations in knee joint synovial fluid and in serum from patients with various inflammatory arthritides were studied using an enzymelinked immunosorbent assay. Patients with reactive arthritis, calcium pyrophosphate arthropathy, and juvenile rheumatoid arthritis (age 5 2 0 years) had the highest synovial fluid concentrations. These values differed significantly (P < 0.001) from those in patients with rheumatoid arthritis, psoriatic arthropathy, and chronic HLA-B27-associated arthropathy . Rheumatoid arthritis patients receiving low-dose prednisolone treatment had higher synovial fluid (P = 0.006) and serum (P <: 0.001) proteoglycan concentrations than did those taking nonsteroidal antiinflammatory drugs or slowacting antirheumatic drugs. Serum proteoglycan concentrations were near the detection limits, and did not correlate with levels found in paired samples of knee joint synovial fluid. Patients with calcium pyrophosphate arthropathy had the highest mean serum level of proteoglycan. This assay of proteoglycan antigens is a From the